利润表（Pacific Biosciences of California Inc）
| 2023年三季报 | 2023年中报 | 2023年一季报 | 2022年年报 | 2022年三季报 | 2022年中报 | 2022年一季报 | |
|---|---|---|---|---|---|---|---|
| 起始日期 | 2023-01-01 | 2023-01-01 | 2023-01-01 | 2022-01-01 | 2022-01-01 | 2022-01-01 | 2022-01-01 |
| 截止日期 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 |
| 报表类型 | 合并报表 | 合并报表 | 合并报表 | 合并报表 | 合并报表 | 合并报表 | 合并报表 |
| 报表年结日 | 1231 | 1231 | 1231 | 1231 | 1231 | 1231 | 1231 |
| 原始币种 | 美元 | 美元 | 美元 | 美元 | 美元 | 美元 | 美元 |
| 上市前/上市后 | 上市后 | 上市后 | 上市后 | 上市后 | 上市后 | 上市后 | 上市后 |
| 营业收入(元) | 142,164,000.00 | 86,473,000.00 | 38,900,000.00 | 128,304,000.00 | 100,951,000.00 | 68,640,000.00 | 33,173,000.00 |
| 主营收入(元) | 142,164,000.00 | 86,473,000.00 | 38,900,000.00 | 128,304,000.00 | 100,951,000.00 | 68,640,000.00 | 33,173,000.00 |
| 营业成本(元) | 98,955,000.00 | 61,166,000.00 | 29,139,000.00 | 79,269,000.00 | 57,056,000.00 | 38,292,000.00 | 19,018,000.00 |
| 主营成本(元) | 98,955,000.00 | 61,166,000.00 | 29,139,000.00 | 75,564,000.00 | 57,056,000.00 | 38,292,000.00 | 19,018,000.00 |
| 其他业务成本(元) | - | - | - | 3,705,000.00 | - | - | - |
| 毛利(元) | 43,209,000.00 | 25,307,000.00 | 9,761,000.00 | 49,035,000.00 | 43,895,000.00 | 30,348,000.00 | 14,155,000.00 |
| 减：研发费用(元) | 142,626,000.00 | 95,112,000.00 | 48,939,000.00 | 193,000,000.00 | 150,377,000.00 | 103,285,000.00 | 52,937,000.00 |
| 减：营销费用(元) | 123,822,000.00 | 80,391,000.00 | 39,818,000.00 | 160,854,000.00 | 115,851,000.00 | 79,056,000.00 | 39,804,000.00 |
| 减：折旧与摊销(元) | 741,000.00 | - | - | - | - | - | - |
| 减：其他营业费用(元) | 22,939,000.00 | 14,231,000.00 | 12,256,000.00 | 2,377,000.00 | -2,221,000.00 | -6,501,000.00 | -1,063,000.00 |
| 营业利润(元) | -246,919,000.00 | -164,427,000.00 | -91,252,000.00 | -307,196,000.00 | -220,112,000.00 | -145,492,000.00 | -77,523,000.00 |
| 加：利息支出(元) | -10,772,000.00 | -7,184,000.00 | -3,630,000.00 | -14,690,000.00 | -11,042,000.00 | -7,378,000.00 | -3,697,000.00 |
| 加：其他收入(支出)(元) | 24,301,000.00 | 15,796,000.00 | 6,867,000.00 | 7,638,000.00 | 1,290,000.00 | -23,000.00 | -279,000.00 |
| 税前利润其他项目(元) | -2,033,000.00 | -2,033,000.00 | - | - | - | - | - |
| 持续经营税前利润(元) | -235,423,000.00 | -157,848,000.00 | -88,015,000.00 | -314,248,000.00 | -229,864,000.00 | -152,893,000.00 | -81,499,000.00 |
| 减：所得税(元) | -10,706,000.00 | - | - | - | - | - | - |
| 持续经营净利润(元) | -224,717,000.00 | -157,848,000.00 | -88,015,000.00 | -314,248,000.00 | -229,864,000.00 | -152,893,000.00 | -81,499,000.00 |
| 净利润(元) | -224,717,000.00 | -157,848,000.00 | -88,015,000.00 | -314,248,000.00 | -229,864,000.00 | -152,893,000.00 | -81,499,000.00 |
| 归属于母公司股东净利润(元) | -224,717,000.00 | -157,848,000.00 | -88,015,000.00 | -314,248,000.00 | -229,864,000.00 | -152,893,000.00 | -81,499,000.00 |
| 归属于普通股股东净利润(元) | -224,717,000.00 | -157,848,000.00 | -88,015,000.00 | -314,248,000.00 | -229,864,000.00 | -152,893,000.00 | -81,499,000.00 |
| 每股收益 | |||||||
| 基本每股收益－普通股(元) | -0.90 | -0.64 | -0.36 | -1.40 | -1.03 | -0.68 | -0.37 |
| 摊薄每股收益－普通股(元) | -0.90 | -0.64 | -0.36 | -1.40 | -1.03 | -0.68 | -0.37 |
| 其他全面收益(元) | 2,925,000.00 | 2,079,000.00 | 2,841,000.00 | -3,678,000.00 | -5,173,000.00 | -4,370,000.00 | -2,998,000.00 |
| 全面收益总额(元) | -221,792,000.00 | -155,769,000.00 | -85,174,000.00 | -317,926,000.00 | -235,037,000.00 | -157,263,000.00 | -84,497,000.00 |
| 公告日期 | 2023-11-03 | 2023-08-04 | 2023-05-04 | 2023-02-28 | 2022-11-08 | 2022-08-08 | 2022-05-06 |
| 会计准则 | 美国会计准则 | 美国会计准则 | 美国会计准则 | 美国会计准则 | 美国会计准则 | 美国会计准则 | 美国会计准则 |
| 审计意见 | |||||||
| 核数师 |